Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression
Darshan S. Chandrashekar, Balabhadrapatruni V. S. K. Chakravarthi, Alyncia D. Robinson, Joshua C. Anderson, Sumit Agarwal, Sai Akshaya Hodigere Balasubramanya, Marie‐Lisa Eich, Akhilesh Kumar Bajpai, Sravanthi Davuluri, Maya S. Guru, Arjun S. Guru, Gurudatta Naik, Deborah L. Della Manna, Kshitish K. Acharya, Shannon Carskadon, Upender Manne, David K. Crossman, James E. Ferguson, William E. Grizzle, Nallasivam Palanisamy, Christopher D. Willey, Michael R. Crowley, George J. Netto, Eddy S. Yang, Sooryanarayana Varambally, Guru Sonpavde
Topics & Concepts
KinomeBladder cancerBiologyCancer researchKinaseTyrosine kinaseDasatinibTyrosine-kinase inhibitorCancerSignal transductionCell biologyMyeloid leukemiaGeneticsImatinibBladder and Urothelial Cancer TreatmentsFerroptosis and cancer prognosisRenal cell carcinoma treatment